Persistent activation of the transcription factor, signal transducer and activator of transcription 3 (Stat3) has been shown to mediate several oncogenic features in many types of cancers, including melanoma. In this study, we investigated whether lentiviral (LV) delivery of Stat3-targeting short hairpin RNA (shRNA; LV-shStat3) to K1735-C4 melanoma cells modulates antitumor immunity. Three shStat3 sequences, starting at the position 446, 830 and 1412, were cloned into a mir30 cassette. A shRNA with scrambled sequence served as a control. Transduction with LV-shStat3 resulted in downregulation of Stat3 in vitro. The latter coincided with low cell viability, a reduced expression of survivin and matrix metalloproteinase (MMP)-2. A single injection of LV-shStat3 in K1735-C4 tumors efficiently downregulated Stat3 in vivo and resulted in reduction of both vascular endothelial growth factor secretion and in myeloid-derived suppressor cell (MDSC) numbers. In contrast, we observed an increase in interleukin-6 and interferon-g secretion, mature dendritic cells (DCs) and CD8 þ T cells. Both DCs and CD8 þ T cells displayed enhanced activity, whereas granulocytic MDSCs lost their suppressive capacity upon Stat3 downregulation. Importantly, a single injection of LV-shStat3 was sufficient to reduce tumor growth, hence prolong survival of tumor-bearing mice. These data demonstrate that Stat3 downregulation in melanoma reinvigorates existing antitumor immunity.
INTRODUCTION
Melanoma is a highly malignant tumor of the melanocytes and is responsible for the majority of skin cancer-related deaths. Complete surgical resection either or not combined with chemoand radiotherapy is often curative in an early stage of the disease. However, once the cancer has spread beyond the limits of surgical resection, the chance of achieving a complete remission and longterm survival is small. 1 Herein lies the difficulty, as melanoma is characterized by its early tendency to metastasize throughout the body. Therefore, it is not surprising that several additional strategies are under investigation for the treatment of melanoma. These include, vaccination of patients with ex vivo-modified dendritic cells (DCs), adoptive T-cell transfer, adjuvant therapy using for instance granulocyte-macrophage colony-stimulating factor, interferon (IFN)-a or antibodies that block critical immune checkpoint (for example, anti-CTLA-4 antibodies), the use of small molecule inhibitors targeting mitogen-activated protein kinases signaling (for example, v-raf murine sarcoma viral oncogene homolog B1 and mitogen activated protein kinase/extracellular signal-regulated kinase kinase inhibitors) and combinations thereof. [2] [3] [4] [5] [6] [7] [8] These strategies all impact on antimelanoma immune responses, offering incremental improvement over standard care, although none of them offer a breakthrough in terms of antitumor activity for all patients. Therefore, the search for molecular targets that show therapeutic promise is still ongoing.
In recent years, the transcription factor signal transducer and activator of transcription 3 (Stat3) has emerged as an interesting therapeutic target in the treatment of cancer because its tight control as a transiently activated transcription factor is often deregulated, resulting in its persistent activation. Deregulated Stat3 activation has been implicated in many oncogenic features, as Stat3 controls the transcription of a variety of genes involved in the regulation of critical functions, such as cell differentiation, proliferation, apoptosis, angiogenesis, metastasis and immune responses. 9 Persistent Stat3 activation has also been described in melanoma. 9, 10 In melanoma, it has been correlated to large tumor diameter and depth, lymph node metastasis, high expression of MMP-2 and -9, and poor patient survival, highlighting its potential as a molecular target. 10, 11 In this study, we validated Stat3 as a molecular target for therapeutic intervention in melanoma. To that end, Stat3 was downregulated in K1735-C4 melanoma cells using lentiviral vectors encoding Stat3-targeting short hairpin RNA (shRNA; LV-shStat3). We demonstrate that Stat3 downregulation negatively impacts on tumor-promoting events, such as tumor cell viability and invasiveness as well as the function of granulocytic myeloid-derived suppressor cells (MDSCs). Importantly, effective downregulation of Stat3 enhanced the activity of immune effector cells including DCs and CD8 þ T cells, and was shown to have therapeutic benefit.
RESULTS

In vitro downregulation of Stat3 impairs tumor cell survival and invasiveness
To downregulate Stat3, we transduced the melanoma cell line K1735-C4 with either LV-shSTAT3-446, -830 or -1412. Cells transduced with lentiviral vectors (LVs) harboring an shRNA with a scrambled sequence (LV-shCTRL) served as a control. Several parameters were evaluated 3 days later. Flow cytometry demonstrated that on average 71.7 ± 7.7% of the K1735-C4 cells were enhanced green fluorescence protein positive and thus transduced (data not shown). Western blot analysis demonstrated complete downregulation of phosphorylated Stat3 (Stat3P) and a reduction in total Stat3 upon transduction with LV-shStat3-446 and -1412 (Figure 1a) . Downregulation of Stat3 impacted on tumor cell viability, as shown by Annexin-V/7-Aminoactinomycin D staining (Figure 1b) . This reduction in cell viability was linked to a loss of survivin expression. The latter was most pronounced upon transduction with LV-shStat3-1412 (Figure 1a) . In addition, zymography demonstrated that LV-shStat3-1412-transduced cells produce less MMP-2, suggesting a reduction in their invasive behavior (Figure 1c) .
In vivo downregulation of Stat3 modulates the tumor environment To evaluate the impact of Stat3 downregulation in vivo on modulation of the tumor and its environment, we continued with LV-shStat3-1412 (further referred to as LV-shStat3) because the in vitro results showed that this shSTAT3 had the strongest effect. As we previously demonstrated that direct injection of LVs into tumor tissue, mainly but not exclusively transduced tumor cells, 12 we administered 10 7 transducing units of LV-shCTRL or LV-shStat3 to the subcutaneously grown tumor of mice. Tumors injected with phosphate-buffered saline (PBS; MOCK) served as a control. Tumors were resected 3 days later, after which several assays were performed. Tumor cell lysates were subjected to western blot analysis, confirming downregulation of Stat3P and to a lesser extent of total Stat3 (Figure 2a) . To analyze the impact of Stat3 downregulation on the tumor environment, we evaluated the secretion of vascular endothelial growth factor, interleukin-6 and IFN-g by bulk tumor cells. Enzyme-linked immunosorbent assay demonstrated a decrease in vascular endothelial growth factor secretion and an increase in the secretion of interleukin-6 and IFN-g Fig. 2b . Flow cytometric analysis of tumor-associated immune cells demonstrated an increase in mature DCs (CD11c Figure 3a) . These sorted CD11c þ cells were added to allogeneic, carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled CD8 þ T cells. Four days later, proliferation of T cells was assessed by flow cytometry, whereas IFN-g secretion was determined by enzyme-linked immunosorbent assay. CD11c þ cells from LV-shStat3-treated tumors induced strong T-cell proliferation and production of IFN-g when compared with CD11c þ cells from control groups (Figures 3b-d ).
CD8
þ T cells in LV-shStat3-treated tumors are functional
As we observed a higher number of CD8 þ T cells in LV-shStat3-treated tumors, we next sorted tumor-resident CD8 þ T cells using MACS ( Figure 4a ) and evaluated their ability to proliferate and produce IFN-g when stimulated with allogeneic bone marrow-derived DCs. We demonstrated that CD8 þ T cells from LV-shStat3-treated tumors were highly functional, whereas CD8 þ T cells from control groups were unable to expand or produce IFN-g (Figures 4b and c) . LV-shCTRL or LV-shStat3. First, CD11b þ cells were sorted by MACS, after which these were divided into CD11b þ Ly6C þ and CD11b þ Ly6G þ MDSCs using the MACS technology ( Figure 5a ). To evaluate their suppressive activity, these MDSCs were added to allogeneic, CFSE-labeled CD8 þ T cells that were stimulated with anti-CD3/CD28 beads. Four days later, we measured the T-cell proliferation and secretion of IFN-g. Both were high in the absence of MDSCs. Addition of MDSCs from mice treated with PBS (MOCK) or LV-shCTRL abrogated both T-cell proliferation and IFN-g production, irrespective of the MDSC subtype. Similar results were obtained with monocytic MDSCs (CD11b þ Ly6C þ ) from LV-shStat3-treated mice. In contrast, T cells stimulated in the presence of granulocytic MDSCs (CD11b 
DISCUSSION
Targeting of Stat3 to undermine the malignant phenotype of tumor cells and to revert tumor-mediated immunosuppression is a well-established concept. However, whether or not Stat3 disruption alone is sufficient to reinvigorate antitumor immunity is still a matter of debate. Several approaches have been developed to interfere with Stat3 at the protein level, that is, by inhibiting its dimerization, phosphorylation and DNA binding, as well as to interfere with Stat3 at the mRNA level, that is, through viral-or nonviral-mediated RNA interference. 13 These approaches have been applied in several tumor models and have highlighted the potential of Stat3 disruption as a means to modulate tumor cell viability and invasive behavior. [14] [15] [16] [17] [18] In melanoma, the effect of Stat3 disruption has been mainly studied by RNA interference in the B16 model. Although Kortylewski et al. 19 showed therapeutic efficacy of Stat3 knockdown, others only showed short-term effects of Stat3 disruption 20 or even argued that Stat3 downregulation in itself does not suffice but rather acts synergistically along with anticancer vaccination. 21 In the current study, we report on the shRNA-mediated Stat3 knockdown in the highly metastatic, less immunogenic K1735-C4 melanoma model, demonstrating that in vivo Stat3 downregulation indeed has therapeutic potential. Several factors might explain the difference in efficacy between the a fore mentioned studies. A first explanation might be found in the method of small-interfering RNA (siRNA) delivery. The method of delivery will dictate which cells will be preferentially modified, tumor cells versus immune cells. In this context, it has to be mentioned that lentiviral vectors have a long history of efficient transgene delivery to several tumor cell types including melanoma. 22, 23 In addition, we recently demonstrated that intratumoral injection of lentiviral vectors results in the modification of mainly tumor cells. 12 In contrast, delivery of synthetic siRNA, especially when delivered as a CpG DNA chimera, might preferentially modify myeloid immune cells. 19 In addition, the vector used for siRNA delivery might already impact on antitumor immunity. This is certainly the case when using a CpG DNA chimera. Although lentiviral vectors preferentially transduce tumor cells upon intratumoral injection, it has to be noted that lentiviral vectors were shown to activate immune cells. [24] [25] [26] A second explanation might be found in the efficacy of Stat3 knockdown. Although RNA interference is a validated tool, the ability of a given siRNA to silence gene expression depends on several factors such as base pair matching with the target mRNA and the secondary structure of the target mRNA, thus accessibility of the complementary target sequence. 27 Indeed, of the three shRNAs used in this study, only LV-shStat3-446 and -1412 were shown to mediate the downregulation of Stat3. Surprisingly, only LV-shStat3-1412 mediated efficient downregulation of survivin and MMP-2 in vitro, highlighting that different shRNAs might promote a different outcome. Thus, the method of RNA interference (vector, cell type and efficacy) will have a major impact on the downstream effects.
As Stat3 expression in tumor cells negatively influences multiple subsets of immune cells, 28 we hypothesized that the enhanced survival of K1735-C4-bearing mice observed upon intratumoral injection of LV-shStat3 could be partially due to immune effector cell activation. We evaluated the cytokine profile in the tumor milieu, the percentage of immune cells and their activation. We demonstrated a reduction in secretion of vascular endothelial growth factor, which has been linked to reduced angiogenesis. 17 In contrast, we demonstrated an increase in secretion of interleukin-6, which is a first indication of breakdown of the immunosuppressive tumor environment. 29 Moreover, we observed high levels of IFN-g, which might point toward an increased effector immune cell function. 30, 31 The latter was evidenced as we observed a higher number of mature DCs and CD8 þ T cells upon Stat3 downregulation. Both tumor-resident immune effector cell population were highly active. Although Alshamsan et al. 20 reported that splenic DCs from B16-bearing mice treated with Stat3-targeting siRNA were more functional, our report demonstrates the importance of tumor-associated immune cells in the reversal of systemic tolerance. An observation that corroborates this statement is the reduction in the overall number of MDSCs, which might be correlated to the reduction of vascular endothelial growth factor, a factor described to induce MDSC expansion. 32 Importantly, also the suppressive activity of granulocytic MDSCs was reduced. Although, the number of monocytic MDSCs was reduced upon Stat3 disruption, we were unable to demonstrate changes in their suppressive behavior. The mechanism behind this selective modulation of MDSC functionality remains to be evaluated. In any case, the interesting outcome on immune cell changes within LV-shStat3-treated tumors demonstrates how subtle changes in molecular components can alter immune cell infiltrates and functionality.
Taken together, our work suggests that disruption of Stat3 signaling in the tumor not only reduces local immunosuppression but also induces robust antitumor immune responses.
MATERIALS AND METHODS
Mice and cell lines
Female mice (C57BL/6 and C3H3), 6-12 weeks old , were purchased from Harlan (Horst, The Netherlands). Animals were handled according to the institutional guidelines. Moreover, experiments involving laboratory animals were approved by the Ethical Committee for use of laboratory animals of the Vrije Universiteit Brussel (Brussels, Belgium).
The mouse melanoma cell line K1735-C4 was a kind gift from IJ Fidler (University of Texas, USA). Human embryonal kidney 293T cells were purchased from the American Type Culture Collection (Rockville, MD, USA). Both cell lines were cultured as described. 12 
Production and characterization of lentiviral vectors
The packaging plasmid pCMVDR8.9 and the VSV.G encoding plasmid pMD.G were a gift from D Trono (University of Geneva, Switzerland). The plasmid pHR 0 -trip-CMV-Ires-eGFP-SIN was described. 33 The Stat3 shRNA starting at the position 446 (5 0 -ATTCATAATCTCTTGGGTGAA-3 0 ), 830 (5 0 -AATGCAGGATCTGAATGGAAC-3 0 ) and 1412 (5 0 -AAGAGGGTCTCGGAAA TTTAAC-3 0 ) were obtained from Integrated DNA Technologies (Coralville, IA, USA) and cloned in the mir30 cassette of the plasmid pFcdGW (a gift from J Zhang, Third Military Medical University, China). Subsequently, the shStat3 containing mir30 cassette was excised using EcoRI-XhoI. This fragment was ligated into the pUC207F plasmid that was also digested with EcoRI and XhoI. Then the fragment was cloned into the pHR 0 -trip-CMV-Ires-eGFP-SIN using the restriction enzymes BamHI and XbaI. These constructs are referred to as LV-shStat3-446, -830 and -1412, respectively. All enzymes were purchased via Thermo Fisher Scientific from Fermentas (Aalst, Belgium). The lentiviral transfer vector encoding nontarget shRNA with scrambled sequence (LV-shCTRL) a kind gift from Professor H Heimberg (Beta Cell Neogenesis, Vrije Universiteit Brussel). The production and characterization of LVs was performed as described. 12 
Transduction of cells with lentiviral vectors
In vitro and in vivo transduction of cells was performed as described. 12 One day before transduction, 1 Â 10 5 cells were plated in 2 ml culture medium in a six-well plate. Transduction was performed by addition of LVs at a multiplicity of infection of 10. Three days later, cell viability was evaluated by Annexin-V/7-AAD staining (Becton Dickinson, Bornem, Belgium) and supernatants were subjected to zymography to assess the presence of MMP-2 and MMP-9.
Ten to twelve days before in vivo transduction, 3 Â 10 5 K1735-C4 cells were inoculated subcutaneously at the tail base and grown to a palpable tumor of about 200 mm 3 , after which 1 Â 10 7 transducing units of LVs were administered into the tumor. To evaluate the tumor environment upon inoculation of Stat3 À / À cells, subcutaneously implanted cells were grown to a tumor size of about 900 mm 3 .
Preparation of single-cell suspension
Single-cell suspensions from in vivo grown tumors were prepared as described. 12 
Western blot
The preparation of cell lysates, protein quantification, gel electrophoresis and protein transfer to a nitrocellulose membrane were performed as described. 12 Polyclonal rabbit antibodies recognizing survivin (Santa Cruz Biotechnology, Heidelberg, Germany) and monoclonal mouse antibodies recognizing Stat3P and Stat3T (Cell Signaling Technology, Bioké , Leiden, The Netherlands) were used as primary antibodies. An anti-rabbit or mouse IgG horseradish peroxidase-conjugated antibody (Cell Signaling Technology) was used for detection. An horseradish peroxidaseconjugated antibody recognizing b-actin (Cell Signaling Technology) was used for normalization. Antibody binding was visualized using enhanced chemoluminescence (Pierce, VWR International Inc., Leuven, Belgium).
Gelatin zymography
Gelatin zymography was performed using serum-free Dulbecco's Modified Eagle's medium (Sigma-Aldrich, Bornem, Belgium) conditioned for 24 h by tumor cells (1 Â 10 6 cells per ml) treated, as indicated. Media were electrophoresed under nonreducing conditions on a 10% SDS-polyacrylamide gel electrophoresis containing 1 mg ml À 1 of gelatin (Merck, Laufelfingen, Switzerland). The gel was washed twice in 2% Triton X-100 for 30 min to remove SDS and incubated overnight in 0.05 mol l À 1 of Tris buffer (pH 7.6) containing 10 mmol l À 1 CaCl 2 and 3 mmol l À 1 NaN 3. Subsequently, the gels were stained with Coomassie brilliant blue and destained in 40% methanol/10% acetic acid. Gelatinolytic activity was identified as a clear band on a blue background. The 72-and 110-kDa bands correspond to MMP-2 and MMP-9, respectively.
Flow cytometry
Staining of cellular markers was performed as described. 33 Allophycocyaninconjugated antibodies against CD11c, CD8, Ly6G and Foxp3, fluorescein isothiocyanate-conjugated antibodies against CD86, CD11b and CD4, phycoerythrin-conjugated antibodies against CD25 and PD-1 (Becton Dickinson), phycoerythrin-cyanin7-conjugated antibodies against Ly6C (BioLegend, San Diego, CA, USA) and biotinylated antibodies against CD80 and Gr-1 (prepared in-house) were applied. Biotinylated antibodies were detected using streptavidin-fluorochrome conjugates (Becton Dickinson). Data were acquired on a FACSCanto flow cytometer (Becton Dickinson) and analyzed using FACSDiva (Becton Dickinson) software.
Allogeneic mixed lymphocyte reaction
Tumor-derived (C3H3) or spleen-derived (C57BL/6) CD8 þ T cells were sorted by positive selection using MACS . Subsequently, these were labeled with 10 mM of CFSE (Molecular Probes Inc., Leiden, The Netherlands) and cocultured at a stimulator-to-responder ratio of 1-to-10 with allogeneic antigen-presenting cells. In particular, tumor-derived CD8 þ T cells were cocultured with bone marrow-derived DCs (C57BL/6), whereas spleenderived CD8 þ T cells (C57BL/6) were cocultured with tumor-derived CD11c þ cells that were sorted by MACS from tumors that were treated as indicated. Four days after the start of the coculture, proliferation of T cells was determined by the dilution of CFSE (flow cytometry). In addition, supernatants collected 4 days after coculture were subjected to enzyme-linked immunosorbent assay to determine the IFN-g secretion (eBoscience, San Diego, CA, USA).
MDSC assay
Single-cell suspensions of tumors treated as indicated above were sorted into CD11b þ Ly6G þ and CD11b þ Ly6C þ MDSCs using the MACS technology (Miltenyi Biotec). Briefly, single-cell suspensions were depleted of non-CD11b þ cells after which the enriched CD11b þ fraction was further separated into Ly6G þ and Ly6C þ cells. These cells (C3H3) were cultured with sorted, CFSE-labeled, spleen-derived CD8 þ T cells (C57BL/6) at a stimulator-to-responder ratio of 1-to-10 in the presence of anti-CD3/anti-CD28 antibody-coated microbeads (Invitrogen, Life Technologies, Oslo, Norway). Basal (no stimulation) and maximal (anti-CD3/anti-CD28 stimulation) proliferation of the CD8 þ T cells was assessed for reference.
Four days after the start of the coculture, dilution of CFSE was determined by flow cytometry, whereas secretion of IFN-g was determined by enzyme-linked immunosorbent assay.
